Drug Trial Radar · NCT07252739
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Nov 15, 2029
Study completion May 31, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Conditions
- Malignant Neoplasm
Interventions
MK-1084Drug
Oral Administration
PembrolizumabBiological
Intravenous administration
CetuximabBiological
Intravenous administration
Sacituzumab tirumotecan (sac-TMT)Biological
Injection powder for intravenous infusion
Rescue medicationDrug
Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 \[Hl\] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with a Dose Limiting Toxicity (DLT)Time frame: Up to approximately 21 days
- Percentage of Participants who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 84 months
- Percentage of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 84 months
- Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 84 months
Locations
40 sites in 14 countries. Site status is shown where the registry gives one.
Clermont Oncology Center ( Site 0041)
Clermont, Florida · Recruiting
Sanford Health Roger Maris Cancer Center ( Site 0039)
Fargo, North Dakota · Recruiting
Sanford Cancer Center Oncology Clinic ( Site 0038)
Sioux Falls, South Dakota · Recruiting
Fundacion Arturo Lopez Perez ( Site 0167)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión ( Site 0160)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0168)
Santiago, Region M. de Santiago, Chile · Recruiting
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
Nanjing, Jiangsu, China · Recruiting
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
Nanchang, Jiangxi, China · Recruiting
Zhongshan Hospital Fudan University ( Site 0319)
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital, Sichuan University ( Site 0315)
Chengdu, Sichuan, China · Recruiting
Kuopion Yliopistollinen Sairaala ( Site 0261)
Kuopio, Northern Savonia, Finland · Recruiting
Vaasan Keskussairaala ( Site 0263)
Vaasa, Pohjanmaa, Finland · Recruiting
Turku University Hospital ( Site 0262)
Turku, Southwest Finland, Finland · Recruiting
HYKS Syöpätautien klinikka ( Site 0260)
Helsinki, Uusimaa, Finland · Recruiting
Evangelismos General Hospital of Athens ( Site 0200)
Athens, Attica, Greece · Recruiting
Hong Kong Integrated Oncology Centre ( Site 0232)
Central, Hong Kong · Recruiting
Queen Mary Hospital ( Site 0230)
Hong Kong, Hong Kong · Recruiting
Hong Kong United Oncology Centre ( Site 0231)
Kowloon, Hong Kong · Recruiting
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
Milan, Lombardy, Italy · Recruiting
Deventer Ziekenhuis ( Site 0272)
Deventer, Overijssel, Netherlands · Recruiting
Leids Universitair Medisch Centrum ( Site 0273)
Leiden, South Holland, Netherlands · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Severance Hospital Yonsei University Health System ( Site 0080)
Seoul, South Korea · Recruiting
Hospital Universitario Virgen de la Macarena ( Site 0093)
Seville, Spain · Recruiting
Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
Bangkok, Bangkok, Thailand · Recruiting
Faculty of Medicine Siriraj Hospital ( Site 0350)
Bangkok, Bangkok, Thailand · Recruiting
Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
Adana, Turkey (Türkiye) · Recruiting
Koç Üniversitesi Hastanesi ( Site 0142)
Adana, Turkey (Türkiye) · Recruiting
Liv Hospital Ankara ( Site 0146)
Ankara, Turkey (Türkiye) · Recruiting
Hacettepe Universite Hastaneleri ( Site 0140)
Ankara, Turkey (Türkiye) · Recruiting
Erciyes University ( Site 0145)
Talas, Kayseri, Turkey (Türkiye) · Recruiting
VISION PARTNER Medical Centre ( Site 0135)
Kyiv, Ukraine · Active not recruiting
LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
Kyiv, Ukraine · Recruiting
COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
Cherkasy, Cherkasy Oblast, Ukraine · Recruiting
Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine · Recruiting
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine · Recruiting
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine · Recruiting
Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
Lviv, Lviv Oblast, Ukraine · Recruiting
Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
Vinnitsya, Vinnytsia Oblast, Ukraine · Recruiting
Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
Uzhhorod, Zakarpattia Oblast, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.